<DOC>
	<DOC>NCT02962895</DOC>
	<brief_summary>This study will determine the dose-response relationship of VAY736 for key efficacy and safety parameters</brief_summary>
	<brief_title>Safety and Efficacy of VAY736 in Patients With Primary Sjogren's Syndrome (pSS)</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Sjogren's Syndrome</mesh_term>
	<criteria>Fulfilled revised European US consensus criteria for pSS Seropositive at screening for antiRo/SSA antibodies Documented salivary/lacrimal gland biopsy result confirming pSS diagnosis prior to the baseline visit Secondary Sjogren's syndrome Use of other investigational drugs Active viral, bacterial or other infections Positive hepatitis B, hepatitis C, HIV or tuberculosis test results at screening</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>